Phase II
Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.
The press release has been shrouded with controversy, and the company’s stock fell 16% despite the seemingly optimistic results.
OcuTerra Therapeutics aims to exchange watching and waiting for active treatment with a non-invasive eyedrop that reaches the retina and, therefore, allows treatment to occur much earlier in the disease.
Biogen announced it was exercising its option to participate in Genentech’s development of mosunetuzumab under a long-standing collaboration for antibodies targeting CD20.
Oak Hill Bio has a pipeline that includes two programs with Phase II proof-of-concept data in rare diseases with significant unmet needs.
You are what you eat, and your defense system notices that.
Altimmune announced Monday that the U.S. Food and Drug Administration (FDA) has approved a Phase II clinical trial for investigational new obesity drug pemvidutide.
The decision came after the Phase IIb study results demonstrating a statistically significant decrease in non-HDL-C and statistically significant reductions in triglycerides and ANGPTL3.
Clinical trial news definitely picked up this final week of January. Here’s a look.
Alzamend Neuro is looking to commence a Phase II multiple ascending dose study of lead compound, AL001, in Alzheimer’s disease during the second quarter of this year.
PRESS RELEASES